Nuclear factor-kappaB p65/relA silencing induces apoptosis and increases gemcitabine effectiveness in a subset of pancreatic cancer cells - Wikidata - awgldk - TriplyDB

Nuclear factor-kappaB p65/relA silencing induces apoptosis and increases gemcitabine effectiveness in a subset of pancreatic cancer cells

Nuclear factor-kappaB p65/relA silencing induces apoptosis and increases gemcitabine effectiveness in a subset of pancreatic cancer cells

http://www.wikidata.org/entity/Q35486194

about

Pachymic acid inhibits growth and induces apoptosis of pancreatic cancer in vitro and in vivo by targeting ER stress Up-regulation of miR-200 and let-7 by natural agents leads to the reversal of epithelial-to-mesenchymal transition in gemcitabine-resistant pancreatic cancer cells Chronic Pancreatitis and Pancreatic Cancer Pristimerin causes G1 arrest, induces apoptosis, and enhances the chemosensitivity to gemcitabine in pancreatic cancer cells A genome-wide association study of overall survival in pancreatic cancer patients treated with gemcitabine in CALGB 80303 S100P antibody-mediated therapy as a new promising strategy for the treatment of pancreatic cancer.Molecular profiling of direct xenograft tumors established from human pancreatic adenocarcinoma after neoadjuvant therapy.Boswellic acid suppresses growth and metastasis of human pancreatic tumors in an orthotopic nude mouse model through modulation of multiple targets.Arginine deiminase augments the chemosensitivity of argininosuccinate synthetase-deficient pancreatic cancer cells to gemcitabine via inhibition of NF-κB signaling Mutant KRas-Induced Mitochondrial Oxidative Stress in Acinar Cells Upregulates EGFR Signaling to Drive Formation of Pancreatic Precancerous Lesions.Downregulation of TRAF2 mediates NIK-induced pancreatic cancer cell proliferation and tumorigenicity Restoring sensitivity to oxaliplatin by a novel approach in gemcitabine-resistant pancreatic cancer cells in vitro and in vivo.Mutant KRAS-induced expression of ICAM-1 in pancreatic acinar cells causes attraction of macrophages to expedite the formation of precancerous lesions.Overcoming drug resistance in pancreatic cancer.MiR-196a promotes pancreatic cancer progression by targeting nuclear factor kappa-B-inhibitor alpha The C-terminal region of Bfl-1 sensitizes non-small cell lung cancer to gemcitabine-induced apoptosis by suppressing NF-κB activity and down-regulating Bfl-1.Differential modulation of nicotine-induced gemcitabine resistance by GABA receptor agonists in pancreatic cancer cell xenografts and in vitro Vitamin E δ-tocotrienol augments the antitumor activity of gemcitabine and suppresses constitutive NF-κB activation in pancreatic cancer.Inhibition of AKT2 enhances sensitivity to gemcitabine via regulating PUMA and NF-κB signaling pathway in human pancreatic ductal adenocarcinoma.The role of Akt activation in the response to chemotherapy in pancreatic cancer Selective Nuclear Export Inhibitor KPT-330 Enhances the Antitumor Activity of Gemcitabine in Human Pancreatic Cancer Nonproteolytic properties of murine alternatively spliced tissue factor: implications for integrin-mediated signaling in murine models.Curcumin Induces Pancreatic Adenocarcinoma Cell Death Via Reduction of the Inhibitors of Apoptosis Knockdown of clusterin sensitizes pancreatic cancer cells to gemcitabine chemotherapy by ERK1/2 inactivation.Targeting the NF-κB and mTOR pathways with a quinoxaline urea analog that inhibits IKKβ for pancreas cancer therapy.Relevance of Sp Binding Site Polymorphism in WWOX for Treatment Outcome in Pancreatic Cancer.Autophagy and cancer.Propofol induces apoptosis and increases gemcitabine sensitivity in pancreatic cancer cells in vitro by inhibition of nuclear factor-κB activity The PRKD1 promoter is a target of the KRas-NF-κB pathway in pancreatic cancer.RETRACTED: 3,3'-Diindolylmethane enhances chemosensitivity of multiple chemotherapeutic agents in pancreatic cancer.KRas, ROS and the initiation of pancreatic cancer Challenges of drug resistance in the management of pancreatic cancer.NF-κB as a target for pancreatic cancer therapy.Design of small molecules targeting transcriptional activation by NF-κB: overview of recent advances.Liposomal siRNA nanocarriers for cancer therapy.Back to the drawing board: Re-thinking the role of GLI1 in pancreatic carcinogenesis.Vitamins in pancreatic cancer: a review of underlying mechanisms and future applications.Maspin mediates the gemcitabine sensitivity of hormone-independent prostate cancer.Pegylated arginine deiminase synergistically increases the cytotoxicity of gemcitabine in human pancreatic cancer TRAF6 is over-expressed in pancreatic cancer and promotes the tumorigenicity of pancreatic cancer cells.

P2860

Q21090555-047A9A5E-BB73-4174-B6FD-990003DF16A5 Q24651034-AB9F88D5-85CC-4804-B152-F9943DB7A2DE Q27025915-18D604F1-F4E7-47BC-95C6-C5CDE07B9474 Q28482913-B09927DF-E945-4D2C-83D2-A2B66C0FDA53 Q28943270-1771C60F-A59B-46F9-8246-6BA14606C1DF Q33685170-EA6CDBA9-43B9-4A32-9D34-771DDF312456 Q33956574-5E140FB4-7340-4F08-A2F6-B405727E76B9 Q34069637-9CAF3A1D-6520-48ED-8312-363E27F1D786 Q34305783-F7B42280-88B4-47E9-8F7C-9B0659307FA3 Q34517052-CD112FAF-0D30-437C-8A10-BEBBCAE290D5 Q34542594-E7CEF3B0-55F7-4D76-BAB2-F350E3194A66 Q34573492-1DE23CC4-A007-4082-8A1E-B6F05EB7389D Q34943207-0DA83F70-6EC6-4F82-8727-9C23221A94B7 Q35036615-1B604CF9-D413-480D-9910-8F31433DB9F1 Q35087835-4C6F408B-D741-41D3-AE5A-9A159748161D Q35194201-33240118-170E-472D-863B-1BFED8A510CB Q35280995-E7DCE731-40D8-4B5B-81AA-6C71A3539C37 Q35613168-14BCB7F5-2931-4A6F-A739-61B952FC2EEA Q35719620-216FC061-7A83-41DC-B61D-F88FDED6C653 Q36020360-9C27AFC8-0293-456D-A423-55BEF80FB7C0 Q36078792-05C920E8-6D8E-4841-A159-AA535B667DE1 Q36130930-F59A800B-5614-4C45-8F87-79E9935E107E Q36373429-EAE5C8E3-10DA-47BD-A571-96ADF754AC64 Q36579884-40E6FB49-23CF-40A9-A5FA-F523CE810820 Q36778047-04EDDAC1-0C1B-4687-ADB3-E635916B9D4D Q36877896-301CB03B-3E11-4D28-B891-69CD8AB22303 Q37102158-D0604414-085B-4EB6-80F5-DCD29CD5B644 Q37142216-6493BCE4-06F8-4F6E-BED8-E590539A920E Q37271741-C8E6778A-FB0C-44CE-AD86-AE3FBEB9AB06 Q37345627-1C627B6F-E894-4BE2-A95D-40E2A82CC631 Q37673906-4F64DDAA-8277-4B5F-8748-D5A1FAB707D3 Q37799830-D5370DBE-398F-4A58-B7D6-C316752EF5A8 Q37996435-5BB3FD39-EE28-4089-AFA5-234F21053307 Q38089908-C30C7E41-A45B-434C-8BCA-F1ABC730FDEC Q38175250-7C63BF75-B73F-48CF-91C5-EAF9524E84CA Q38263531-8E907F63-E8ED-490B-A598-ABB2DAAB8B22 Q38633074-E03E4404-3AC4-4D25-8D3A-63AE07D30FA5 Q38826034-0407A424-2B64-4921-BBAF-C2D6FE91D3C6 Q38929570-02AC76BD-F55F-48F0-9CCF-4B0A36F8363D Q38953657-65DEB258-6ED5-4584-9F5F-BBFAFEF97BA3

P2860

Nuclear factor-kappaB p65/relA silencing induces apoptosis and increases gemcitabine effectiveness in a subset of pancreatic cancer cells

http://www.wikidata.org/entity/Q35486194

description

2008 nî lūn-bûn

@nan

2008 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2008 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

name

Nuclear factor-kappaB p65/relA ...... set of pancreatic cancer cells

@ast

Nuclear factor-kappaB p65/relA ...... set of pancreatic cancer cells

@en

type

label

Nuclear factor-kappaB p65/relA ...... set of pancreatic cancer cells

@ast

Nuclear factor-kappaB p65/relA ...... set of pancreatic cancer cells

@en

prefLabel

Nuclear factor-kappaB p65/relA ...... set of pancreatic cancer cells

@ast

Nuclear factor-kappaB p65/relA ...... set of pancreatic cancer cells

@en

P1433

Q35486194-EDCEA644-5DFF-4E65-A9AD-0E046478ABF2

P1476

Q35486194-95FB8BA6-4F46-41B9-B88D-0DDE67490A3B

P2093

Q35486194-16308C27-08D4-430A-A353-8BCD771BE646

Q35486194-1783DEBB-EDEF-4269-986F-3DFD06CA8212

Q35486194-198192F7-08A5-4B9A-B7DC-CE6197CEB317

Q35486194-25914F8E-27C6-428F-AC7E-41DA01A229A5

Q35486194-4213136F-18D1-4A86-817C-7511D78EAA30

Q35486194-43FF195C-C826-43AD-B8D1-7AF7DD91FBA0

Q35486194-74C25FA0-DDA3-4729-9BFC-F847368B05F5

Q35486194-867767BB-F729-4973-B568-C93F3B7C9EC7

Q35486194-8FD5F4BC-D955-4898-9123-732C44F04257

Q35486194-C118A8B1-2660-4D4B-B67B-4DDF685C3E7C

P2860

Q35486194-0344633B-3A70-453B-832D-D1C472479CA0

Q35486194-097E062F-CD0A-443D-93D7-CDAD0A455EB3

Q35486194-0D80259D-B092-4C90-9476-224CCDFE4B6D

Q35486194-16ED0A45-EBFB-4E57-A587-CEC66B965AE6

Q35486194-1956FA22-8551-428A-BFE9-A9B7501FD422

Q35486194-1D8CE512-6562-487E-A18C-87D31E788C9E

Q35486194-20B88A8D-6ED7-4874-939A-06E7E7AC07B8

Q35486194-212EC191-AD8F-4BEC-89B1-9488D608A3B5

Q35486194-24F616D9-80EB-49F1-972C-E553F61A563F

Q35486194-30034A82-5BFE-48DC-80D9-1A8BC8447ED8

P304

Q35486194-2667D556-3B68-4E11-AAFF-626B7A4F44A6

P31

Q35486194-7B6FCECB-11F4-487A-A6D6-C4832DA23803

P356

Q35486194-772469C0-3DC4-463A-9541-1C1D80AFC047

P407

Q35486194-D48D7B1B-680B-4856-BEBF-37FF033B6D9F

P433

Q35486194-E0770F33-EE2A-4F12-B230-660B38D47AE5

P478

Q35486194-59B433C7-76F7-47F6-A45B-34C390FB32E6

P577

Q35486194-07079366-4D39-498F-97DF-F5D71FB6BB47

P698

Q35486194-4C5DD805-8FB6-4389-A6CC-C3667C61129B

P932

Q35486194-47E8A613-D55E-46F8-97B0-7D1FA5BCCFC7

P356

1078-0432.CCR-08-1539

P1433

Clinical Cancer Research

P1476

Nuclear factor-kappaB p65/relA ...... set of pancreatic cancer cells

@en

P2093

Anil K Sood

http://www.w3.org/2001/XMLSchema#string

Baoan Ji

http://www.w3.org/2001/XMLSchema#string

Craig D Logsdon

http://www.w3.org/2001/XMLSchema#string

David J McConkey

http://www.w3.org/2001/XMLSchema#string

Gabriel Lopez-Berestein

http://www.w3.org/2001/XMLSchema#string

Pablo E Vivas-Mejia

http://www.w3.org/2001/XMLSchema#string

Pavel A Levin

http://www.w3.org/2001/XMLSchema#string

Tameyoshi Yamamoto

http://www.w3.org/2001/XMLSchema#string

Thiruvengadam Arumugam

http://www.w3.org/2001/XMLSchema#string

Vijaya Ramachandran

http://www.w3.org/2001/XMLSchema#string

P2860

Aberrant rel/nfkb genes and activity in human cancer

Shaping the nuclear action of NF-kappaB

Cancer statistics, 2006

Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group

Inhibiting HIV-1 infection in human T cells by lentiviral-mediated delivery of small interfering RNA against CCR5.

Inactivation of nuclear factor kappaB by soy isoflavone genistein contributes to increased apoptosis induced by chemotherapeutic agents in human cancer cells.

Determinants of resistance to 2',2'-difluorodeoxycytidine (gemcitabine).

NFkappaB-dependent chemoresistance in solid tumors.

Immortal human pancreatic duct epithelial cell lines with near normal genotype and phenotype.

Nuclear factor-kappaB inhibitors as sensitizers to anticancer drugs.

P304

8143-8151

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1078-0432.CCR-08-1539

http://www.w3.org/2001/XMLSchema#string

P407

P433

24

http://www.w3.org/2001/XMLSchema#string

P478

14

http://www.w3.org/2001/XMLSchema#string

P577

2008-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19088029

http://www.w3.org/2001/XMLSchema#string

P932

4403242

http://www.w3.org/2001/XMLSchema#string